Definition

What Is Alzheimer's Disease?

Alzheimer's disease is the most common form of dementia (~60-80% of cases), characterized by progressive cognitive decline, memory loss, and behavioral changes. Pathologically defined by amyloid-beta plaques and tau neurofibrillary tangles, with widespread neuron loss particularly in the hippocampus and cortex.

Increasingly understood as a multifactorial disease driven by insulin resistance in the brain ("Type 3 Diabetes"), chronic neuroinflammation, mitochondrial dysfunction, oxidative stress, and vascular factors. The Bredesen protocol and emerging precision-medicine approaches identify modifiable contributors in each patient.

Critical insight: pathology begins 15-20 years before symptoms. The window for prevention is now, middle age. Lifestyle interventions (Mediterranean/MIND diet, exercise, sleep, social engagement, cognitive activity) can delay onset by 5+ years in those with genetic risk (APOE4).

💡 Key Insight: ~45% of dementia cases are attributable to 14 modifiable risk factors (Lancet Commission 2024): hearing⁵ loss, LDL cholesterol, depression, head injury, hypertension, smoking, obesity, diabetes, alcohol, physical inactivity, social isolation, air pollution, vision loss, low education. Address these and you significantly reduce risk.

Stages of Alzheimer's Disease

🌱 Mild Cognitive Impairment (MCI)

Subtle memory or thinking problems noticeable but not interfering with daily life. ~15% per year progress to dementia. CRITICAL window for intervention, lifestyle changes can prevent progression.

🌗 Mild to Moderate Alzheimer's

Recent memory loss, word-finding difficulty, disorientation, mood changes. Difficulty with complex tasks. Lasts 2-10 years. Patients gradually need more help.

🌑 Severe / Late-Stage

Loss of recognition of loved ones, language, mobility, swallowing. 24/7 care required. Death usually from pneumonia or other complications, 8-12 years average from diagnosis.

Signs & Symptoms

Symptoms of Alzheimer's & Dementia

Memory loss is the classic symptom but other cognitive domains often decline first. Early recognition matters, the earlier intervention starts, the more decline can be prevented.

🧠 Cognitive Symptoms

📝

Short-Term Memory Loss

Forgetting recent conversations, repeating questions, misplacing items, missing appointments. The earliest and most prominent symptom. Long-term memories preserved early.

💬

Word-Finding Difficulty

Pausing mid-sentence to search for words, substituting general terms ("thing" for specific items), trouble following conversations. Vocabulary shrinks.

🗺️

Disorientation & Getting Lost

Getting lost in familiar places, confusion about time/date, difficulty following directions. Spatial navigation declines early.

🧮

Executive Function Decline

Trouble planning, managing finances, following recipes, problem-solving. Multi-step tasks become difficult. Bills go unpaid, finances mismanaged.

🌀 Behavioral & Functional

😔

Mood & Personality Changes

Depression, anxiety, apathy, irritability. Withdrawal from hobbies and social activities. Personality changes, may become more or less outgoing than before.

🌙

Sleep Disturbances & Sundowning

Disrupted sleep-wake cycle. "Sundowning", confusion and agitation worsening late afternoon/evening. Reduced REM sleep impairs memory consolidation.

😟

Agitation, Suspicion, Hallucinations

In later stages: paranoia (someone's stealing from me), hallucinations, agitation, wandering. Often distressing for caregivers.

🍴

Loss of Functional Independence

Progressive inability to bathe, dress, toilet, eat, walk. Activities of Daily Living (ADLs) decline. Eventually 24/7 care needed.

Diagnosis

How to Diagnose Alzheimer's & Dementia

🧠 Cognitive & Clinical Assessment

📋 Cognitive Screening Tests

MoCA (Montreal Cognitive Assessment), more sensitive than MMSE for early disease. MMSE (Mini-Mental State Exam). Mini-Cog (quick screening).

🧪 Comprehensive Neuropsychological Testing

2-4 hour battery assessing memory, language, executive function, visuospatial skills. Most sensitive for early detection and differential diagnosis.

📡 Brain MRI

Hippocampal atrophy, generalized cortical atrophy. Rules out other causes, strokes, tumors, normal pressure hydrocephalus, vascular dementia.

📡 PET Imaging

Amyloid PET, Tau PET, FDG-PET. Confirms Alzheimer's pathology in vivo. Expensive but increasingly available. New blood-based amyloid tests are emerging.

🩸 Modifiable Risk Workup

🩸 Metabolic Panel

HbA1c, fasting insulin, lipid panel. Brain insulin resistance is core to Alzheimer's. Target HbA1c <5.7, fasting insulin <7.

🩸 B12², Folate, Homocysteine

B12 deficiency mimics dementia and worsens it. Elevated homocysteine (>14) doubles dementia risk. MTHFR genetic variants matter.

🩸 Vitamin D, Thyroid, Heavy Metals

Low vitamin D (<30) increases risk. Hypothyroidism mimics dementia. Heavy metal toxicity (mercury, aluminum) contributes, test if exposure suspected.

🧬 APOE Genotype (Optional)

APOE4 carriers (1 or 2 copies) have higher risk. Information allows earlier and more aggressive prevention. Ethical considerations, counseling recommended.

Treatment Comparison

Holistic vs. Conventional Treatment

🌿 HOLISTIC

💊 CONVENTIONAL

🌿

Holistic / Functional Approach

Address modifiable risk factors aggressively. FINGER trial showed 25% reduction in cognitive decline with lifestyle intervention.

Best Evidence

FINGER trial: multi-domain lifestyle intervention reduced cognitive decline 25% over 2 years

Prevention Power

~45% of cases attributable to 14 modifiable factors (Lancet Commission 2024)

Prevention Window

Begin midlife (40s-50s); pathology starts 15-20 years before symptoms

For MCI

Lifestyle interventions can prevent progression to dementia

Multi-Domain Lifestyle Intervention (FINGER-Style)

MIND diet or Mediterranean diet, reduces Alzheimer's risk by ~35-53%. Olive oil, leafy greens, berries, nuts, fish, whole grains, beans.
Aerobic exercise 150+ min/week, increases BDNF (brain-derived neurotrophic factor), hippocampal volume. Strongest single intervention.
Resistance training 2-3x/week, preserves muscle, glucose control, cognitive function
Sleep 7-9 hours/night, glymphatic system clears amyloid during deep sleep. Treat sleep apnea aggressively.
Social engagement, strongly protective. Isolation increases dementia risk ~50%.
Cognitive stimulation, learning new skills, languages, puzzles. Builds cognitive reserve.
Stress reduction, meditation, yoga, breathwork. Chronic cortisol shrinks hippocampus.
Optimize cardiometabolic health, BP <130/80, HbA1c <5.7, LDL <100, fasting insulin <7
Address hearing loss, single largest modifiable risk factor. Use hearing aids.
Quit smoking, reduce alcohol, less is better and none is best, <7 drinks/week or none
Address depression, increases risk 50%. Treat aggressively.
Avoid head injuries, helmets, fall prevention, contact sports caution
Reduce air pollution exposure, HEPA filter at home, monitor outdoor AQI

✅ What the evidence actually shows. The FINGER trial randomized 1,260 at-risk older adults to a multidomain programme of diet, exercise, cognitive training and vascular risk management, and found a modest benefit to cognition. That is the strongest evidence in this area and it is worth acting on. The Bredesen ReCODE protocol is often cited alongside it; it has been published as small uncontrolled case series, has not been tested against a control group, and should not be treated as equivalent. No intervention has been shown in a controlled trial to reverse established Alzheimer's disease. Addressing several modifiable factors together, and starting early, is still the best available approach.³

💊

Conventional / Medical Approach

Cholinesterase inhibitors, memantine, new amyloid-targeting infusions for early disease

First-Line

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine), modest symptomatic benefit

Moderate-Severe

Add memantine (Namenda), NMDA receptor modulator

Early Disease (NEW)

Lecanemab (Leqembi), donanemab (Kisunla), anti-amyloid monoclonals⁷, modest disease modification

Honest Reality

No conventional drug stops progression; lifestyle has stronger evidence

Standard Pharmacologic Treatment

Donepezil (Aricept): cholinesterase inhibitor. Once-daily. Modest cognitive benefit; side effects: GI, vivid dreams, bradycardia.
Rivastigmine (Exelon): available as patch (better tolerated). Used for Alzheimer's and Parkinson's dementia.
Galantamine (Razadyne): cholinesterase inhibitor + nicotinic receptor modulator
Memantine (Namenda): NMDA receptor antagonist for moderate-severe disease. Often combined with cholinesterase inhibitor.
Lecanemab (Leqembi): IV infusion every 2 weeks. Removes amyloid plaques. Modest slowing (~27%) of cognitive decline. Risk: ARIA (amyloid-related imaging abnormalities), brain swelling/bleeds, particularly in APOE4 homozygotes.
Donanemab (Kisunla): similar mechanism, given until plaques cleared
Behavioral symptom management: SSRIs for depression, careful antipsychotics for severe agitation (black-box warning, increased mortality)
Caregiver support: essential. Respite care, adult day programs, eventual long-term placement

⚠️ Honest Truth: Conventional drugs offer modest symptom relief but don't stop disease progression. Anti-amyloid drugs slow decline by ~25-30% but have serious side effects (ARIA, infusion reactions). Best results come from COMBINING medication with intensive lifestyle modification.

Nutritional Strategy

The MIND Diet for Brain Health

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) reduces Alzheimer's risk by 53% with strict adherence and 35% with moderate adherence (Rush University).

✅ Prioritize Daily/Weekly:

🥬 Leafy Greens (6+/week)

Spinach, kale, collards, arugula. In an observational cohort, people eating a daily serving had cognitive test scores equivalent to those of people roughly 11 years younger. An association among people who differ in many ways, not a demonstrated reversal.⁴ Folate, vitamin K, lutein support brain function.

🫐 Berries (2+/week)

Blueberries, strawberries, blackberries. Anthocyanins cross blood-brain barrier. Slow cognitive aging by ~2.5 years per study.

🐟 Fatty Fish (1+/week)

Wild salmon, sardines, mackerel, herring. DHA is structural to neuronal membranes. Low DHA correlates with smaller brain volume.

🌰 Nuts (5+/week)

Walnuts (omega-3), almonds (vitamin E), pistachios. 1 oz daily, reduces inflammation, improves cognition.

🫒 Olive Oil (Daily Primary Fat)

Extra virgin olive oil, polyphenols (oleocanthal) clear amyloid in animal models. 2-4 tbsp daily.

❌ Limit Strictly:

🍞 Refined Grains & Added Sugar

Drive brain insulin resistance ("Type 3 Diabetes"). White bread, pastries, sweets, sodas. Causal in cognitive decline.

🧀 Saturated Fat & Cheese (<1/week)

Original MIND diet limits cheese. Some evidence saturated fat worsens cognitive decline. Moderate intake of higher-fat dairy may be neutral.

🍔 Fried/Fast Food (Rare)

Pro-inflammatory advanced glycation end-products (AGEs), trans fats. Strong association with cognitive decline.

🍷 Heavy Alcohol

>7 drinks/week increases dementia risk. Heavy use directly neurotoxic. Light/moderate use ambiguous, when in doubt, abstain.

🥩 Red & Processed Meat

Limit to <4 servings red meat/week. Avoid processed meats. Heme iron + AGEs increase neuroinflammation.

Supplement Protocol

Evidence-Based Supplements

Supplements support but don't replace the lifestyle foundation. Best evidence for omega-3, B vitamins, vitamin D, and choline-related compounds.

Supplement	Mechanism & Evidence	Suggested Dose	Timing	Notes
Omega-3 (EPA/DHA)	DHA structural to neurons. Slows brain atrophy. Higher doses needed in APOE4 carriers due to reduced DHA transport.	2,000-4,000mg EPA+DHA/day	With fat meal	Higher dose for APOE4 carriers. Test omega-3 index (target >8%).
Vitamin D3	Low D associated with 50% higher dementia risk. Receptors throughout brain. Anti-inflammatory.	Test 25-OH-D first and set the dose with your clinician (titrate to 40 to 60 ng/mL, the Endocrine Society's preferred range)	With fat meal	Pair with K2 200mcg. If you take warfarin, agree any vitamin K supplement with the clinician managing your anticoagulation before starting or stopping it: vitamin K antagonises warfarin, and changing your intake destabilises the INR. Consistency matters more than avoidance. This does not apply in the same way to direct oral anticoagulants such as apixaban or rivaroxaban.
B-Complex (B12, B6, Folate)	Lower homocysteine, high homocysteine doubles dementia risk. VITACOG trial showed 30-50% reduction in brain atrophy.	B12 1,000mcg + B6 20mg + Folate 800mcg/day (methylated forms)	Morning with food	Use methylcobalamin, P5P, methylfolate. Test homocysteine.
Curcumin (Bioavailable)	Anti-inflammatory, anti-amyloid in animal models. Crosses blood-brain barrier. Promising small human trials.	500-1,500mg/day (liposomal or with piperine)	With fat meal	Standard curcumin poorly absorbed.
Lion's Mane Mushroom	Stimulates nerve growth factor (NGF). Small trial showed cognitive improvement in MCI.	1,000-3,000mg/day	Divided doses	Effects diminish after stopping. Choose extracts standardized to beta-glucans/hericenones.
Phosphatidylserine	Brain membrane phospholipid. May improve memory in early-stage cognitive decline.	100-300mg/day	With meals	Sunflower-derived preferred over soy.
Magnesium L-Threonate	Only form that crosses blood-brain barrier effectively. May improve cognitive function.	1,500-2,000mg/day (providing ~144mg elemental Mg)	Evening	Pricey but unique BBB penetration. Branded MagteinÂ®. The upper intake level for supplemental magnesium is 350 mg/day; above that the usual effect is loose stools rather than harm, but it is worth knowing.
Citicoline (CDP-Choline)	Increases acetylcholine and phospholipid synthesis. Improves attention, memory in vascular and Alzheimer's dementia.	250-1,000mg/day	Morning	Well-tolerated. Synergistic with cholinesterase inhibitors.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed 24 August 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.⁸ Be careful in this area, because desperation and expensive protocols meet here. No intervention has been shown in a controlled trial to reverse established Alzheimer's disease. What the evidence does support is worth doing: managing cardiovascular risk, treating hearing loss, exercise, sleep, social and cognitive engagement, and not smoking are associated with lower dementia risk, and a multidomain programme showed modest cognitive benefit in a large randomized trial. Treat any protocol promising reversal, any supplement stack sold for memory, and any clinic charging heavily for either, with scepticism proportional to the price. If cognitive change is new, get assessed: depression, thyroid disease, B12 deficiency, sleep apnoea and medication effects all cause reversible cognitive impairment and are missed regularly.

On what Alzheimer's is: a progressive neurodegenerative disease with amyloid plaques and tau tangles, beginning fifteen to twenty years before symptoms. It is the commonest cause of dementia but not the only one; vascular, Lewy body and frontotemporal dementias differ in presentation and management, and mixed pathology is common. ↩
On reversible causes, which is the first practical step. Depression, hypothyroidism, vitamin B12 deficiency, obstructive sleep apnoea, alcohol, and anticholinergic and sedative medication all cause cognitive impairment that improves when addressed. A structured assessment looks for these, and finding one changes everything. ↩
On multidomain intervention, and on ReCODE. The FINGER trial randomized 1,260 at-risk older adults to diet, exercise, cognitive training and vascular risk management, and found a modest benefit on cognitive performance; it is the strongest evidence in this area and the basis for taking the lifestyle approach seriously. The Bredesen ReCODE protocol is frequently cited alongside it but has been published as small uncontrolled case series without a control group, and its results cannot be interpreted the same way. Presenting the two as equivalent evidence is not defensible, particularly where the protocol carries substantial cost. ↩
On diet: the MIND diet, combining Mediterranean and DASH elements, is associated with slower cognitive decline in observational cohorts. A randomized trial of the MIND diet published in N Engl J Med in 2023 found no significant difference in cognitive change compared with a mild calorie-restricted control, with both groups improving. The observational association is real; the trial did not confirm a specific effect. Eat this way for cardiovascular reasons, which are well supported, and treat cognitive benefit as unproven. ↩
On modifiable risk: the Lancet Commission identifies a set of potentially modifiable risk factors across the lifespan, including hearing loss, hypertension, obesity, smoking, depression, physical inactivity, diabetes, social isolation, excessive alcohol, traumatic brain injury and air pollution. Hearing loss is among the largest and most treatable, and hearing aids are among the more concrete things available. ↩
On supplements: no supplement has been shown to prevent or treat Alzheimer's disease. Ginkgo biloba failed in large prevention trials including GEM. Vitamin E has limited and inconsistent evidence in established disease and carries risk at high doses. B vitamins lower homocysteine with no reliable cognitive benefit except possibly where deficiency exists. Coconut oil, ketones and most memory formulations lack supporting trials. ↩
On new drug treatments: anti-amyloid monoclonal antibodies slow decline modestly in early disease, with meaningful risks including brain swelling and microhaemorrhage, substantial cost and demanding monitoring. Whether the benefit is clinically noticeable is genuinely debated. This belongs with a specialist rather than in a supplement discussion. ↩
National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic.